Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Third indication studied for SGN-30 in new phase II trial

Sep. 29, 2004

Enrollment completed in phase III study of Canvaxin

Sep. 28, 2004

Pivotal study begins for FavId for follicular B-cell NHL

Sep. 28, 2004

IND submission to begin clinical testing of Tarvacin

Sep. 28, 2004

IDM cleared to begin U.S. phase II trial of Uvidem

Sep. 23, 2004

Phase III trial for Ceplene fails to meet primary endpoint

Sep. 23, 2004

New phase I data on the safety profile of cantuzumab mertansine in advanced cancer

Sep. 21, 2004

Novel DNA cancer vaccine enters phase I trial

Sep. 21, 2004

Phase I trial investigates GVAX prostate cancer vaccine with MDX-010

Sep. 15, 2004

H3 Pharma and DSM sign manufacturing agreement for SC-1

Sep. 14, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...